Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380674 | 0.92 | PPARG (0.46) | PPARGAGTR2AGTR1 | |
| SCHEMBL683359 | 0.90 | AGTR2 (0.57) | PPARGAGTR2AGTR1 | |
| SCHEMBL683639 | 0.89 | AGTR2 (0.65) | PPARGAGTR2AGTR1 | |
| SCHEMBL18088504 | 0.89 | AGTR2 (0.56) | AGTR2 | |
| SCHEMBL3804684 | 0.88 | PPARG (0.54) | PPARGAGTR1 | |
| SCHEMBL2844345 | 0.87 | AGTR1 (0.48) | AGTR2AGTR1 | |
| SCHEMBL13175977 | 0.87 | PPARG (0.52) | PPARGAGTR2AGTR1 | |
| SCHEMBL18087887 | 0.86 | AGTR2 (0.59) | AGTR2 | |
| SCHEMBL13954876 | 0.85 | PPARG (0.49) | PPARGAGTR2AGTR1 | |
| SCHEMBL7015930 | 0.85 | AGTR1 (0.47) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| EP-2068812-B9 | MEDICINAL PACKAGE | TAKEDA PHARMACEUTICAL (JP) | 2012-08-08 | — | — | EP | claimed |
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| EP-1990052-B1 | PHARMACEUTICAL PACKAGE COMPRISING 2-ETHOXY-1-{[2'-(5-OXO-4,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL]METHYL}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL OR 2-CYCLOPROPYL-1-{[2'-(5-OXO-4,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL]METHYL}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL AND A DESICCANT. | TAKEDA PHARMACEUTICAL (JP) | 2012-05-16 | — | — | EP | claimed |
| JP-4795362-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| EP-1863801-B1 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | claimed |
| US-20090012132-A1 | Pharmaceutical Package | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-08 | — | — | US | claimed |
| EP-1990052-A1 | PHARMACEUTICAL PACKAGE | Takeda Pharmaceutical Company Limited (JP) | 2008-11-12 | — | — | EP | claimed |
| JP-2008534434-A | — | — | 2008-08-28 | — | — | JP | claimed |
| EP-1863801-A2 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | claimed |
| WO-2006107062-A2 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-12 | — | — | WO | claimed |
| US-20160008328-A1 | Stable Pharmaceutical Package Comprising Azilsartan Medoxomil | CADILA HEALTHCARE LIMITED (IN) | 2016-01-14 | — | — | US | disclosed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| EP-1990052-A1 | PHARMACEUTICAL PACKAGE | Takeda Pharmaceutical Company Limited (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1863801-A2 | BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107062-A2 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172401-A1 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST | AGTR2, AGTR1, ACE | PPARG 1405/4885AGTR2 1/4885AGTR1 2/4885 |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | PPARG 428/4885AGTR2 2/4885AGTR1 1/4885 |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | AGTR2, AGTR1, ACE | PPARG 1405/4885AGTR2 1/4885AGTR1 2/4885 |
| US-20160008328-A1 | Stable Pharmaceutical Package Comprising Azilsartan Medoxomil | REN, AVPR2, QDPR | PPARG 3426/4885AGTR2 16/4885AGTR1 17/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | PPARG 1211/4885AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.